Hostname: page-component-745bb68f8f-l4dxg Total loading time: 0 Render date: 2025-01-10T15:28:35.986Z Has data issue: false hasContentIssue false
  • English
  • Français

Korean medication algorithm for depressive disorder (KMAP-DD) 2017: Maintenance treatment

Published online by Cambridge University Press:  23 March 2020

D.I. Jon ,
W. Kim ,
H.R. Wang ,
Y.S. Woo ,
J.S. Seo ,
Y.M. Park ,
J.H. Jeong ,
S.H. Shim ,
J.G. Lee  and
K.J. Min
...Show all authors
D.I. Jon
Affiliation:
Hallym University Sacred Heart Hospital, Psychiatry, Anyang, Republic of Korea
W. Kim
Affiliation:
Inje University Seoul Baik Hospital, Psychiatry, Seoul, Republic of Korea
H.R. Wang
Affiliation:
The Catholic University St. Mary Hospital, Psychiatry, Seoul, Republic of Korea
Y.S. Woo
Affiliation:
The Catholic University St. Mary Hospital, Psychiatry, Seoul, Republic of Korea
J.S. Seo
Affiliation:
Konkuk University Chungju Hospital, Psychiatry, Chungju, Republic of Korea
Y.M. Park
Affiliation:
Inje University Ilsan Paik Hospital, Psychiatry, Goyang, Republic of Korea
J.H. Jeong
Affiliation:
The Catholic University St. Vincent Hospital, Psychiatry, Suwon, Republic of Korea
S.H. Shim
Affiliation:
Soonchunhyang University Cheonan Hospital, Psychiatry, Cheonan, Republic of Korea
J.G. Lee
Affiliation:
Inje University Haewoondae Baik Hospital, Psychiatry, Busan, Republic of Korea
K.J. Min
Affiliation:
Chung-Ang University Hospital, Psychiatry, Seoul, Republic of Korea
W.M. Bahk
Affiliation:
The Catholic University St. Mary Hospital, Psychiatry, Seoul, Republic of Korea

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

The international guideline for treating depression has been widely used.

Objectives

The current study focused on the maintenance treatment section of the third revision of Korean Medication Algorithm for Depressive Disorder (KMAP-DD)

Methods

A 44-item questionnaire was used to obtain the consensus of experts regarding pharmacological treatment strategies for depressive disorder. Of the 144 committee members, 79 psychiatrists responded to the survey. Each treatment strategy or treatment option was evaluated with the nine-point scale.

Results

Most clinicians answered to maintain both antidepressants (AD) and atypical antipsychotics (AAP) for psychotic depression in remission state. The duration of AD maintenance: from 19.8 weeks to 46.8 weeks for patients in remission of the first episode, from 34.8 weeks to 78.4 weeks for the second depressive episode, and long-term continuation for three or more depressive episodes. Aripiprazole was the most preferred AAP. The preferred doses of AD and AAP in maintenance treatment were about 75% and 50% of those in acute treatment The maintenance of AAP in the psychotic depression in remission was similar to the AD, although shorter and less.

Conclusions

The maintenance strategies of KMAP-DD 2017 were similar to those of KMAP-DD 2012. Most clinicians preferred to maintain AD for substantial duration after achieving remission. The maintenance of AAP was also preferred, but the duration was shorter than AD.

Disclosure of interest

The authors have not supplied their declaration of competing interest.

Type
e-Poster viewing: Cultural psychiatry
Information
European Psychiatry , Volume 41 , Issue S1: Abstract of the 25th European Congress of Psychiatry , April 2017 , pp. S530
Copyright
Copyright © European Psychiatric Association 2017
Submit a response

Comments

No Comments have been published for this article.